There is no consensus on the association between the tumor necrosis factor- α (TNF- α) gene promoter –308 A/G single nucleotide polymorphisms and bladder cancer risk. To obtain a more precise estimation of this correlation, we conducted a meta-analysis. The PubMed, MEDLINE, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases were searched for relevant published studies. Seven case-control studies with a total of 1,311 cases and 1,436 controls were identified and analyzed. A notable correlation was observed between the TNF- α genotype and bladder cancer grade (AA+GA vs. GG; odds ratio 1.96, 95% confidence interval 1.37–2.80, p = 0.0002). In summary, this meta-analysis demonstrates that the TNF- α –308 AA+GA genotype may be a marker to the tumor-invasive stage of bladder cancer.

Keywords:
Tumor necrosis factor-α, Single nucleotide polymorphism, Bladder cancer, Meta-analysis
1.
Jyothi Lakshmi R, Kartha VB, Murali Krishna C, Solomon JG, Ullas G, Uma Devi P: Tissue Raman spectroscopy for the study of radiation damage: brain irradiation of mice. Radiat Res 2002;157:175–182.
2.
Hassen W, Droller MJ: Current concepts in assessment and treatment of bladder cancer. Curr Opin Urol 2000;10:291–299.
3.
Lutzeyer W, Rubben H, Dahm H: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982;127:250–252.
4.
Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A: Significance of serum tumor necrosis factor-α and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers 2010;25:126–135.
5.
Egger M, Smith GD: Meta-analysis. Potentials and promise. BMJ 1997;315:1371–1374.
6.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.
7.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
8.
Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun Wee J, Kim WJ: Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005;65:70–75.
9.
Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ: Association of bladder tumors and GA genotype of –308 nucleotide in tumor necrosis factor-α promoter with greater tumor necrosis factor-α expression. Urology 2004;64:1052–1056.
10.
Tsai FJ, Lu HF, Yeh LS, Hsu CD, Chen WC: Lack of evidence for the association of tumor necrosis factor-α gene promoter polymorphism with calcium oxalate stone and bladder cancer patients. Urol Res 2001;29:412–416.
11.
Nonomura N, Tokizane T, Nakayama M, Inoue H, Nishimura K, Muramatsu M, Okuyama A: Possible correlation between polymorphism in the tumor necrosis factor-β gene and the clinicopathological features of bladder cancer in Japanese patients. Int J Urol 2006;13:971–976.
12.
Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD: Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet 2008;184:1–8.
13.
Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X: Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005;23:5746–5756.
14.
Marsh HP, Haldar NA, Bunce M, Marshall SE, le Monier K, Winsey SL, Christodoulos K, Cranston D, Welsh KI, Harris AL: Polymorphisms in tumour necrosis factor are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 2003;89:1096–1101.
15.
Honchel R, McDonnell S, Schaid DJ, Thibodeau SN: Tumor necrosis factor-α allelic frequency and chromosome-6 allelic imbalance in patients with colorectal cancer. Cancer Res 1996;56:145–149.
16.
Mann EA, Hibbs MS, Spiro JD, Bowik C, Wang XZ, Clawson M, Chen LL: Cytokine regulation of gelatinase production by head and neck squamous cell carcinoma: the role of tumor necrosis factor-α. Ann Otol Rhinol Laryngol 1995;104:203–209.
17.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195–3199.
18.
Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, Wheeler CM: TNF-α promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 2005;191:969–976.
19.
Berkovic M, Cacev T, Zjacic-Rotkvic V, Kapitanovic S: TNF-α promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2006;84:346–352.
20.
Akkiz H, Bayram S, Bekar A, Ozdil B, Akgollu E, Sumbul AT, Demiryurek H, Doran F: G-308A TNF-α polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol 2009;33:261–264.
21.
Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A, Jia X, Bai J, Chen F, Yu Y, Jin Y, Yu J, Fu S: Polymorphisms of tumor necrosis factor-α and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011;126:763–770.
22.
Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, Mao Y: Polymorphisms of tumor necrosis factor-α are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet 2008;53:479–489.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.